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Association of serum leptin and
adiponectin with anthropomorphic indices
of obesity, blood lipids and insulin
resistance in a Sub-Saharan African
population
Clarisse Noël A. Ayina1*, Jean Jacques N. Noubiap2,3, Laurent Serge Etoundi Ngoa4, Philippe Boudou5,
Jean François Gautier6,7, Michel Karngong Mengnjo8, Jean Claude Mbanya8,9,10 and Eugene Sobngwi8,9,10
Abstract
Background: There is little data on the metabolic effects of adipokines in sub-Saharan African populations. This
study aimed to explore the potential relationship of leptin and adiponectin, with obesity, plasma lipids and insulin
resistance in a Cameroonian population.
Methods: We enrolled 167 men and 309 women aged ≥18 years from the general population in Cameroon. Data
were collected on waist circumference (WC), body mass index (BMI), waist-to-hip ratio (WHR), body fat (BF%),
fasting blood glucose, plasma lipids, adiponectin, leptin, insulin and homeostasis model for assessment of insulin
resistance (HOMA-IR). Pearson’s correlation and multiple stepwise linear regression analyses were used to determine
correlates of leptin and adiponectin serum levels.
Results: The prevalence of obesity was higher in women compared to men (p< 0.0001), and Central obesity which is
more prevalent particularly in women (WC = 42.4 %, WHR = 42.3 %), is almost for 90 % comparable to %BF (42.7 %).
Adiponectin negatively with BMI (r = −0.294, p < 0.0001), WC (r = −0.294, p < 0.0001), %BF (r = −0.122, p = 0.028),
WHR (r = −0.143, p = 0.009), triglycerides (r = −0.141, p = 0.011), HOMA-IR (r = −0.145, p = 0.027) and insulin (r = −0.130,
p = 0.048). Leptin positively correlated with BMI (r = 0.628), WC (r = 0.530), BF% (r = 0.720), (all p < 0.0001); with
DBP (r = 0.112, p = 0.043), total cholesterol (r = 0.324, p < 0.0001), LDL-cholesterol (r = 0.298, p < 0.0001), insulin
(r = 0.320, p < 0.001 and HOMA-IR (r = 0.272, p < 0.0001).
In multiple stepwise regression analysis, adiponectin was negatively associated with WC (β = −0.38, p = 0.001)
and BF% (β = 0.33, p < 0.0001), while leptin was positively associated with BF% (β = 0.60, p < 0.0001), total
cholesterol (β = 0.11, p = 0.02) and HOMA-IR (β = 0.11, p = 0.02). When controlled for gender, HOMA-IR was
found significantly associated to adiponectin (β = 0.13, p = 0.046), but not BF%, while the association
previously found between leptin and HOMA-IR disappeared; BMI and WC were significantly associated with
leptin (β = 0.18, p = 0.04 & β = 0.19, p = 0.02 respectively).
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Conclusion: This study, which includes a population who was not receiving potentially confounding
medications, confirms the associations previously observed of adiponectin with reduced adiposity especially
central adiposity and improved insulin sensitivity. Confirmatory associations were also observed between
leptin and obesity, blood lipids and insulin resistance for the first time in an African population. Gender was
significant covariate interacting with insulin sensitivity/insulin resistance and obesity indexes associations in
this population.
Keywords: Adipokines, Adiponectin, Leptin, Blood lipids, Insulin resistance, Insulin sensitivity, Obesity indices
Background
Africa is experiencing a surge in obesity prevalence and
related morbidity and mortality within the context of
one of the most rapid epidemiological transition in the
world history [1]. Insulin resistance and consequently
type 2 diabetes mellitus are major metabolic sequelae of
obesity. Adipose tissue has been identified as a link be-
tween obesity and insulin resistance [2].
Adipose tissue is now regarded as not just a purely
inert body compartment for excess energy storage, but
rather as an active endocrine and paracrine organ, se-
creting a large number of hormones, cytokines and
growth factors, collectively called adipokines [3]. Some
of them are synthesized exclusively or predominantly by
adipocytes (e.g., adiponectin, leptin), while others origin-
ate from other sources as well (e.g., resistin, chemerin,
proinflammatory cytokines) [4]. Adiponectin and leptin
are of particular interest because of their role in the
regulation of various physiological processes, including
insulin responsiveness, glucose and lipid metabolism, as
well as endothelial function, inflammatory response and
cytokine signaling [4].
Indeed, there is evidence that adiposity, as measured
through body mass index (BMI), and insulin resistance
are associated with circulating levels of leptin and adipo-
nectin; leptin has a positive association with adiposity
and insulin resistance whereas the converse correlation
exists between adiponectin and adiposity and insulin re-
sistance [5–7]. Furthermore, there has been recent inter-
est in the leptin-to-adiponectin ratio (LAR) as a novel
predictor of cardio-metabolic and other chronic disease
outcomes. This ratio has been shown to be associated
with insulin resistance [8, 9], metabolic syndrome [10],
carotid intima-media thickness [11], “at-risk phenotype”
in young severely obese patients [9], and chronic kidney
disease [12], among others.
Adiponectin and leptin circulate in lower concentra-
tions in healthy male compare to female, and is mainly
attributed to lower amounts of hexameric High Molecu-
lar Weight (HMW) form of adiponectin [13, 14], and to
adipose tissue for leptin [15]. Like many other metabolic
hormones, adiponectin, especially its HMW form, is reg-
ulated by the biological clock showing circadian rhythms
with a nocturnal reduction [16]; yet, it’s plasma concen-
tration does not depend on fasting status, show only a
limited intra-personal variation over time. On the other
hand, leptin shows a circadian variation with a moderate
oscillation with their secretion being influenced by regu-
larly eating cycles [17].
Adiponectin and leptin levels vary across ethnic popu-
lations. Higher mean levels of leptin and lower mean
levels of adiponectin have been reported in African-
Americans as compared to subjects of Caucasian ethni-
city [18–21]. However, studies that have investigated the
role of these adipokines in various diseases among
African populations are very scarce. Circulating adipo-
nectin levels were significantly associated with measures
of obesity, serum lipids, and insulin resistance in a study
on West African population [22]. Circulating Adiponec-
tin was reported to be associated with renal function in-
dependent of age and serum lipids in West Africans.
According to their findings, the authors suggest that adi-
ponectin may have clinical utility as a biomarker of renal
function [23]. A study conducted on urban South
African blacks with and without coronary artery disease
(CAD) revealed that leptin differentiated between CAD
patients with and without metabolic syndrome and de-
termined metabolic syndrome status in women and men
[24]. The current study aimed to investigate the poten-
tial relationship between leptin and adiponectin, and
obesity, blood lipids and insulin resistance in the Camer-
oonian population. We were particularly interested in
determining whose of BMI, waist circumference (WC),
waist-to-hip ratio (WHR) and percent body fat (BF %) as
surrogates of adiposity, better correlate with leptin and
adiponectin plasma levels. Data will contribute to a bet-
ter understanding of the metabolic effects of these cyto-
kines and their potential as therapeutic targets and
predictor of cardio-metabolic outcomes in sub-Saharan
Africans.
Methods
Study population
This is a cross-sectional study conducted in May 2010 in
Douala and Edea, two urban cities of the Littoral region of
Cameroon. The study population consisted of individuals
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of both genders aged ≥ 18 years from the general popula-
tion, who accepted to participate in the study after an invi-
tation through radio announcements. Pregnant and
breast-feeding women, as well as subjects with serious
chronic illness, or ongoing or recent (<10 days) acute
illness, or those taking any current medication were
excluded from the study. After applying the exclusion
criteria, 476 participants were included in the study.
Data collection
For each subject, weight was measured in light clothes
with a Seca Scale balance to the nearest 0.1 kg, height
with a calibrated stadiometer, waist circumference (WC)
at midway between the lowest rib and the iliac crest and
hip circumference at the outermost points of the greater
trochanters to the nearest 0.5 cm and waist-to-hip ratio
(WHR) as waist circumference divided by hip cir-
cumference. Body mass index (BMI) was calculated
using the Quetelet’s formula as weight (in kg) divided by
height (in m2). We measured resting blood pressures
twice using standardized procedures with the participant
in a seated position, and after at least 10 min rest with a
validated automated blood pressure measuring device,
the Omron HEM-757 (Omron Corporation, Tokyo,
Japan). The mean of two measures performed at least
three minutes apart was used for all analyses.
Percentage body fat (%BF) was measured by bioelectric
impedance analysis using the OMRON BF 302
(OMRON Matsusaka Co., Tokyo, Japan). After 8–12 h
overnight fast, blood glucose was measured between 7
and 10 am using the Accu-Chek® Compact Plus gluc-
ometer (F. Hoffmann-La Roche AG, Basel, Switzerland)
on total fresh capillary blood samples, and venous blood
samples were obtained from an antecubital vein. Serum
was then separated and stored at −20 °C for lipid mea-
surements and at − 80 °C for further biochemical ana-
lysis. Serum lipids were analyzed within one week after
the collection. Serum cholesterol (TC) (cholesterol oxi-
dase phenol 4-amino antipyrene peroxidase method),
serum triglycerides (TG) (glycerol phosphatase oxidase
− phenol4-amino antipyrene peroxidase method), and
high-density lipoprotein -cholesterol (HDL-c) (choles-
terol oxidase phenol4-amino antipyrene peroxidase
method) were measured on a spectrophotometer (UV
Mini 1240) using Chronolab kits (Chronolab Systems,
Barcelona, Spain). Low-density lipoprotein -cholesterol
(LDL-c) was calculated using the Friedwald’s formula
[25]. Insulin levels were measured using an electroche-
miluminescence immunoassay (Roche Diagnostics, In-
dianapolis, USA), while serum leptin and adiponectin
were measured measured by Radio Immuno Assay (RIA)
using Linco Research kits (Linco Research Inc., St
Charles, Missouri, USA) with the following characteris-
tics: Adiponectin assay coefficient of variation (CV) ≤
10 %; detection limit of 2 ng/ml for 100 μl sample size; a
linearity range of 500 ng/ml for 100 μl sample size.
Leptin assay’s coefficient of variation ≤ 10 % (intra-assay’s
CV ≤ 8.3 % and inter assay’s CV ≤ 6.2 %); a detection
limit of 0.5 ng/ml for 100 μl sample size; a linearity
range of 100 ng/ml for 100 μl sample size. Anthropome-
trical and biochemical measurements were made once
on each participant.
Homeostasis Model Assessment of Insulin Resist-
ance (HOMA-IR) as HOMA − IR = (Fasting insulin ×
Fasting blood glucose) ÷ 22.5.
Definition of anthropomorphic indices of obesity
According to the World Health Organization guidelines,
obesity was defined as BMI ≥30 kg/m2 [26], WC >94 cm
in men and >80 cm in women, WHR ≥0.90 in men and
≥0.85 in women [27]. The BF% cutoffs chosen to define
obesity were the values most frequently cited by inter-
national scientific literature: BF% ≥ 25 for men and ≥ 35
for women [28].
Statistical analysis
Data were coded, entered and analyzed using the Statis-
tical Package for Social Science (SPSS) version 20.0 for
Windows (IBM Corp. Released 2011. IBM SPSS Statis-
tics for Windows, Version 20.0. Armonk, NY: IBM
Corp.). The distribution pattern of the variables was
checked. Normally distributed variables are expressed as
mean with standard deviation (SD). Skewed variables are
reported as median (interquartile range). Skewed vari-
ables were log transformed. The independent sample t-
test was used to compare clinical and biological parame-
ters between men and women. Spearman’s correlation
and multiple stepwise linear regression analyses were
used to determine correlates of leptin and adiponectin
serum levels. Multiple stepwise regression analysis in-
cluded adiponectin and leptin as dependent variables
and on one hand the factors which p < 0.05 from the bi-
variate correlation. These are BMI, WC, BF%, WHR, TG
and HOMA-IR for adiponectin, and BMI, WC, BF%, TC,
TG, LDL-c and HOMA-IR for leptin. WHR was re-
moved from the final model for adiponectin because it
interacts with WC as central obesity index and negative
impact on the model. Each model was controlled for age
and gender. Statistical tests are two tailed. A p value < 0.05
was considered statistically significant.
Ethical considerations
This study was performed in accordance with the guide-
lines of the Helsinki Declaration and was approved by
the National Ethics Committee for Human Health
Research and by the Ministry of Public Health of
Cameroon. Written informed consent was obtained
from all participants.
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Results
A total of 476 subjects (167 men and 309 women) were
enrolled in the study. The median age (interquartile) was
55.0 (23.6) for men and 50.0 (20.0) for women (p < 0.05).
WHR, SBP and DBP were significantly higher in men
(p < 0.05 respectively). Triglycerides, LDL-c024), insu-
lin, adiponectin, leptin, and HOMA-IR were signifi-
cantly higher in women (p < 0.05 respectively)
(Table 1).
Prevalence of obesity using the different
anthropomorphic indexes
The prevalence of obesity using the different obesity
indexes was significantly higher in women than in
men (all p < 0.001). Men, had a higher prevalence of
BF% (11.8 %), BMI and WC showed quasi-equal
prevalence rates (7.4 % & 7.7 % respectively); and a
low WHR prevalence (5.4 %). In women, WC, WHR
and BF% had the higher prevalence than men
(42.7 %, 42.3 % and 42.7 % respectively) and lowest
prevalence of obesity BMI (425.5 %) (Fig. 1). Central
obesity measured with WC and WHR seems to reflect
body fat better than general obesity measured with
BMI in this population.
Correlations between adipokines and anthropomorphic
indexes of obesity, blood pressure, blood lipids and
insulin resistance
As shown in Table 2, adiponectin positively and signifi-
cantly correlated with age (r = 0.200, p < 0.0001) and
negatively correlated with BMI (r = −0.294, p < 0.0001),
WC (r = −0.294, p < 0.0001), WHR (r = −0.143, p = 0.009
and BF% (r = −0.122, p = 0.028). There was no significant
correlation between adiponectin and blood pressure. On
the other hand, adiponectin correlated negatively with tri-
glycerides (r = −0.141, p = 0.011), insulin (r = −0.130, p =
0.048) and HOMA-IR (r = −0.145, p = 0.027).
There was a significantly positive correlation
between leptin and BMI (r = 0.628, p < 0.0001), WC
(r = 0.530, p < 0.0001) and BF% (r = 0.729, p < 0.0001).
Leptin also positively correlated with DBP (r = 0.112,
p = 0.043), total cholesterol (r = 0.324, p < 0.0001),
LDL-cholesterol (r = 0.298, p < 0.0001), Triglycerides
(r = 0.148, p = 0.007), insulin (r = 0.320, p < 0.0001)
and HOMA-IR (r = 0.273, p < 0.0001).
In multiple stepwise regression analysis, WC was
negatively associated with adiponectin (β = −0.38, p <
0.0001, CI: −0.009–−0.0004) and remained unchanged
after control for age and gender; a model that explained
26 % of the variance of adiponectin levels. WC is then
the index of obesity that better predict adiponectin levels
in this population. The positive association between BF%
and adiponectin (β = 0.33, p < 0.0001, CI: 0.004–0.013)
was weakened by age and strongly dependent of gender.
HOMA-IR was negatively associated with adiponection
when controlled for gender (β = −0.125, p = 0.045, CI:
−0.081–0.000). That association was significant (p =
0.05) when age was added in the model. Age may
impact on the relation between insulin resistance
and adiponectin in this population. Age and gender
were both significant covariates positively associated
with adiponectin (β = 0.24, p < 0.0001, CI: 0.002–
0.007 & β = 0.29, p < 0.0001, CI: 0.09–0.22 respect-
ively) (Table 3, Fig. 2).
Leptin was positively associated with BF% (β = 0.60,
p < 0.0001, CI: 0.05–0.08), TC (β = 0.11, p = 0.02)
when controlled for age and gender, a model that
explain 68 % of leptin levels. When controlling for
gender only, BMI and WC were both positively asso-
ciated with leptin (p = 0.04 & p = 0.02 respectively).
Age may strongly influence the relation between
BMI and leptin. Except for BF%, WC was the obesity
index significantly associated to leptin after control
for age and gender. The association of HOMA-IR
with leptin (β = 0. 11, p = 0.02 CI: 0.0–0.29) was
dependent of gender, although reinforcement of age.
Age and gender were both significant covariates
positively associated to leptin (p = 0.001, p < 0.0001
respectively) (Table 4, Fig. 3).
Table 1 Clinical and metabolic characteristics of the study
population
Men (n = 167) Women (n = 309) p value
Age 55 (23) 50 (20) <0.0001
Weight (kg) 71.00 (23.00) 70.00 (25.00) 0.984
Height (m) 1.70 (0.20) 1.60 (0.10) <0.0001
BMI (kg/m2) 25.30 (6.30) 28.00 (6.60) <0.0001
WC (cm) 91.04 ± 12.6 93.58 ± 14.0) 0.091
WHR (cm) 0.91 (0.09) 0.87 (0.09) <0.0001
BF (%) 22.90 (8.62) 34.00 (10.42) <0.0001
SBP (mm Hg) 137 (37) 1128 (33) <0.0001
DBP (mm Hg) 86 (21) 82 (20) 0.006
Blood glucose (mmol/L) 5.0 (1.10) 4.80 (1.15) 0.204
Total Cholesterol (mmol/L) 4.14 (1.07) 4.45 (1.16) 0.05
Triglycerides (mmol/L) 1.20 (0.45) 1.26 (0.35) 0.024
LDL-c (mmol/L) 1.48 (0.97) 1.78 (1.17) 0.031
HDL-c (mmol/L) 2.13 (0.99) 2.14 (0.91) 0.763
Insulin (μU/mL) 2.14 (2.16) 2.73 (2.47) 0.020
HOMA-IR 8.64 (0.25) 11.05 (11.13) 0.031
Adiponectin (μg/mL) 7.65 (5.55) 10.75 (8.90) 0.038
Leptin (ng/mL) 4.80 (6.20) 18.50 (24.40) <0.0001
WC Values are means (standard deviation); except for WC, values are Median
(Interquartile Range)
WC waist circumference, BF% body fat percentage, BMI body mass index, WHR
waist-hip ratio, SBP systolic blood pressure, DBP diastolic blood pressure, LDL-c
low density lipoprotein-cholesterol, HDL-c high density lipoprotein-cholesterol,
HOMA-IR homeostasis model assessment of insulin resistance
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Discussion
During the last decade, several studies demonstrated the
important role of adiponectin and leptin in the regula-
tion of various physiological processes, including insulin
responsiveness, glucose and lipid metabolism, as well as
endothelial function, inflammatory response and cyto-
kine signaling [4]. These adipokines have therefore been
postulated to be strong predictors of cardiometabolic
and other chronic disease outcomes [5–12]. Much more,
adiponectin has been identified as a therapeutic target
and several strategies have been suggested for increasing
its favorable effects [29–31]. This study was designed
to explore the relationships of leptin and adiponectin
with various anthropometric indexes of obesity, blood
lipids and insulin resistance among a Cameroonian
population.
We found that plasma adiponectin concentrations are
positively correlated to age, and negatively related with
BMI, WC, BF%, WHR, triglycerides, insulin levels, and
HOMA-IR. In contrast, leptin plasma levels positively
correlated with BMI, WC, BF%, DBP, total cholesterol,
triglycerides, LDL-cholesterol and insulin levels, and
HOMA-IR. The finding of an inverse relationship be-
tween BMI, WC and BF% is similar to previous reports
in Americans [32], Japanese subjects [33], Pima Indians
and Caucasians [34]. A similar association was also
found among African-American in the Multi-Ethnic
Study of Atherosclerosis (MESA) [35]. In a previous
study, we also found that adiponectin was inversely cor-
related with waist circumference in apparently healthy
Cameroonians [36]. This negative correlation between
adiponectin and these surrogates of obesity may be due
to the fact that adiponectin gene expression is down-
regulated in obesity and its related pathology [12, 32].
Furthermore, we found that except for BMI, WC ex-
hibits the stronger negative correlation with adiponectin
levels. Yet, the responsibility of subcutaneous or visceral
fat in this association is discussed [37, 38]. This result is
in accordance with the observation that cultured adipo-
cytes derived from the intra-abdominal fat depot secrete
Fig. 1 Prevalence rates of obesity within the population using BMI, WC, WHR and BF%
Table 2 Spearman’s correlation coefficients of adiponectin and
leptin
Adiponectin Leptin
r p r p
Age 0.200 <0.0001 −0.115 0.038
BMI −0.294 <0.0001 0.628 <0.0001
WC −0.294 <0.0001 0.530 <0.0001
WHR −0.143 0.009 −0.029 0.599
BF% −0.122 0.028 0.729 <0.0001
SBP 0.009 0.869 0.026 0.643
DBP −0.009 0.871 0.112 0.043
TC −0.070 0.207 0.324 <0.0001
TG −0.141 0.011 0.148 0.007
HDL-c 0.102 0.064 −0.022 0.685
LDL-c −0.061 0.279 0.298 <0.0001
Insulin −0.130 0.048 0.320 <0.0001
HOMA-IR −0.145 0.027 0.273 <0.0001
WC waist circumference, BF% body fat percentage, BMI body mass index, WHR
waist-hip ratio, SBP systolic blood pressure, DBP diastolic blood pressure, TC
total cholesterol, TG triglycerides, LDL-c low density lipoprotein-cholesterol,
HDL-c high density lipoprotein-cholesterol, HOMA-IR homeostasis model
assessment of insulin resistance
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adiponectin more actively than subcutaneous fat derived
adipocytes [39]. In this study, WC was the only obesity
index significantly associated to adiponectin when con-
trolled for age and gender. This finding confirms the
conclusions that WC is the obesity index the better cor-
relate with obesity related diseases [40].
It has been demonstrated that plasma adiponectin
concentrations correlate negatively with insulin resist-
ance (or correlate positively with insulin sensitivity) and
fasting plasma insulin concentrations [32, 34, 41–44].
Likewise, we found that adiponectin levels are negatively
associated with plasma insulin level and HOMA-IR;
however, these associations seem to depend on gender
in this population. These findings support the notion
that adiponectin concentrations could modulate insulin
action. Indeed, of the adipokines, adiponectin may be
the most biologically active in improving insulin sensitiv-
ity. Adiponectin is believed to improve insulin sensitivity
by binding to its receptors including AdipoR1 which is
expressed primarily in skeletal muscle, and AdipoR2
which is expressed most abundantly in the liver. These
receptors mediate the adiponectin-induced increase in
glucose uptake in muscle and the decrease in glucose
production by liver (hepatic gluconeogenesis), respect-
ively [45, 46]. Because of this important role on insulin
sensitivity, adiponectin is currently one of the strongest
biochemical predictors of type 2 diabetes mellitus [47].
However, sex hormons can modify the expression and
activities of PPARγ and its downstream adipokines [48].
Besides its action as an insulin sensitizer, adiponectin
exerts an anti-atherogenic activity by increasing fatty
acid uptake and oxidation through the activation of
AMP activated protein kinase (AMPK), p38-mitogen-
activated protein kinase (MAPK), and peroxisome
proliferator-activated receptor gamma (PPARα) path-
ways [49–52]. We found that plasma adiponectin con-
centrations are negatively correlated with circulating
triglycerides concentrations. These findings are in line
with previous studies which reported that serum levels
of lipids and lipoproteins (triglycerides, LDL-
cholesterol, apolipoprotein A1 and apolipoprotein B)
were significantly increased but HDL-C was decreased
with decreasing adiponectin levels. It is assumed that
the association of adiponectin with lower triglyceride
concentrations is secondary to its insulin-sensitizing
properties [53].
Leptin has been identified as an important protein in-
volved in the weight regulation system, and the absence
of leptin leads to increased appetite and decreased en-
ergy expenditure and subsequently obesity [54]. The
interaction between leptin and fat mass and obesity-
associated (FTO) gene expression is a major mechanistic
pathway underlying the role of leptin in the regulation
of body-weigh [4]. Interestingly, this study confirms the
positive and strong association found between serum
leptin levels and percentage body fat. WC and BMI were
also found associated to leptin after control for gender.
This association of leptin with obesity has been previ-
ously demonstrated in a multi-ethnic population includ-
ing African-Americans [35], as well as in subjects with
various obesity-related pathologies such as in type 2 dia-
betes [44, 55, 56]. Furthermore, we found that leptin
plasma concentrations also positively correlated with
plasma insulin concentrations and HOMA-IR thus insu-
lin resistance. These findings have been reported in pre-
vious studies in type 2 diabetes patients [44, 55, 56]. In
fact, hyperinsulinemia and insulin resistance were re-
ported to induce hyperleptinemia through increased
adiposity [53, 54]. Beside, the positive correlation be-
tween leptin and DBP in this study is in accordance with
observational data associating leptin with cardiovascular
disease [4], as well as the positive association found with
plasma total cholesterol. These associations of leptin with
raised blood pressure and pro-atherogenic blood lipids,
along with its role in insulin resistance and endothelial
dysfunction, in diabetes and hypertension onset, and its
pro-inflammatory activity are the major mechanisms
through which leptin triggers cardiovascular diseases [4].
Table 3 Multiple regression analysis with adiponectin as dependent variable
No control for age
nor gender (R2 = 0.19)
Control for
age (R2 = 0.21)
Control for
gender (R2 =0.20)
Control for gender
and age (R2 = 0.26)
Beta p 95 % CI Beta p 95 % CI Beta p 95 % CI Beta p 95 % CI
Age 0.17 0.01 0.001–0.010 0.24 <0.0001 0.002–0.007
Sex 0.25 <0.0001 0.06–0.19 0.29 <0.0001 0.09–0.22
BMI −0.21 0.10 −0.59–0.05 −0.13 0.39 −0.54–0.21 −0.15 0.19 −0.50–0.10 0.06 0.70 −0.30–0.46
WC −0.38 0.001 −0.01–−0.002 −0.53 <0.0001 −0.18–0.59 −0.32 <0.0001 −0.008–−0.08 −0.37 <0.0001 −0.009–−0.004
BF% 0.33 <0.0001 0.004–0.01 0.21 0.01 0.002–0.01 0.17 0.18 −0.002–0.01 −0.10 0.38 −0.01–0.003
TG −0.09 0.16 −0.33–0.05 −0.06 0.32 −0.28–0.09 −0.07 0.25 −0.30–0.08 −0.08 0.20 −0.30–0.6
HOMA-IR −0.11 0.96 −0.08–0.01 −0.10 0.13 −0.07–0.01 −0.13 0.046 −0.08–0.000 −0.12 0.05 −0.08–0.000
CI Confidence Interval, BMI body mass index, WC waist circumference, BF% body fat percentage, TG triglycerides, HOMA-IR homeostasis model assessment of
insulin resistance
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Our study has a principal strength that this population
was not receiving potentially confounding medications
during the investigation. Nevertheless, this study has
three main limitations. First, its cross-sectional design
prevented us from identifying cause-and-effect ass-
ociations between leptin and adiponectin, and blood
lipids, obesity and insulin resistance. Secondly, we used
HOMA-IR to evaluate insulin sensitivity rather than
gold-standard methods such as the hyperinsulinemic
euglycemic clamp and the frequently sampled-
intravenous glucose tolerance test which, however,
would have been significantly very difficult to perform in
such a population-based study in a resource-limited set-
ting. Despite these shortcomings our study is one the
very few to report on the relationship of leptin and adi-
ponectin with lipid profile, anthropomorphic indexes of
obesity and insulin sensitivity among subjects of African
ancestry. Thirdly, in this study we used a commer-
cially available RIA method (Linco Research Inc.)
which measures only total adiponectin, though recent
Fig. 2 Linear regression presenting the associations of adiponectin with BMI, WC, BF%, triglycerides, insulin and HOMA-IR
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Table 4 Multiple regression analysis with leptin as dependent variable
No control for age nor gender (R2 = 0.60) Control for age (R2 = 0.65) Control for gender (R2 = 0.66) Control for gender and age (R2 = 0.68)
Beta p 95 % CI Beta p 95 % CI Beta p 95 % CI Beta p 95 % CI
Age −0.23 <0.0001 −0.02–−0.01 −0.16 0.001 −0.02–−0.005
Sex 0.35 <0.0001 0.51–1.01 0.24 <0.0001 0.26–0.81
BMI 0.13 0.06 −0.03–0.12 −0.11 0.28 −0.75–0.50 0.18 0.04 0.03–0.09 −0.02 0.99 −0.14–0.12
WC −0,02 0,81 −0,04–0,01 0.07 0.22 −0.02–0.002 0.19 0.02 0.01–0.03 0.22 0.001 0.06–0.07
BF% 0.60 <0.0001 0.05–0.08 0.75 <0.0001 0.07–0.09 0.29 0.001 0.01–0.05 0.48 <0.0001 0.03–0.07
DBP −0,01 0,91 −0,62–0,55 −0.04 0.35 −0.29–0.81 0.06 0.19 −0.18–0.92 0.05 0.23 −0.21–0.88
TC 0.11 0.02 0.07–0.84 0.10 0.02 0.06–0.79 0.12 0.01 0.13–0.85 0.12 0.007 0.14–0.85
TG −0,04 0,35 −0,87–0,31 −0.06 0.14 −0.95–0.14 −0.05 0.22 −0.89–0.21 −0.07 0.09 −0.97–0.08
LDL-c −0,07 0,21 −0,16–0,04 −0.03 0.53 −0.12–0.06 −0.03 0.56 −0.13–0.07 −0.01 0.91 −0.10–0.09
HOMA-IR 0.11 0.02 0.02–0.29 0.11 0.015 0.03–0.28 0.07 0.12 0.02–0.22 0.09 0.03 −0.01–0.26
CI Confidence Interval, WC waist circumference, BF% body fat percentage, BMI body mass index, TC total cholesterol, TG triglycerides, LDL-c low density lipoprotein-cholesterol, HOMA-IR homeostasis model assessment
of insulin resistance
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studies suggest that the high molecular weight type of
adiponectin is biologically active.
Conclusions
This study confirms the associations previously ob-
served between adiponectin and leptin, and obesity,
blood lipids and insulin resistance. Adiponectin is
associated with reduced adiposity, especially ab-
dominal adiposity, improved insulin sensitivity and
lower levels of pro-atherogenic blood lipoproteins.
In spite of the interactions BF% and HOMA-IR
with gender in their association to adiponectin,
adiponectin is thus suggested to be a predictor of
good metabolic and cardiovascular health in this
sub-Saharan African population. Contrariwise, leptin
is strongly associated to anthropometric indexes of
obesity (BMI, WC, WHR, BF%) and obesity-related
adverse effects that trigger cardiovascular disease,
including insulin resistance for the first time in an
African population, increased blood pressure and
Fig. 3 Linear regression presenting the associations of leptin with BMI, WC, %BF, total-cholesterol, LDL-cholesterol and HOMA-IR
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pro-atherogenic blood lipids. The associations of
HOMA-IR, BMI and WC with leptin were related
to gender in this population.
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